Eton Pharmaceuticals (NASDAQ:ETON) Director Jennifer Mckie Adams Sells 50,000 Shares of Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Director Jennifer Mckie Adams sold 50,000 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the transaction, the director directly owned 50,000 shares in the company, valued at approximately $1,624,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Eton Pharmaceuticals Stock Performance

NASDAQ ETON opened at $32.76 on Thursday. The stock has a fifty day simple moving average of $28.80 and a 200-day simple moving average of $21.48. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62. The stock has a market cap of $897.30 million, a PE ratio of -467.93 and a beta of 0.87. Eton Pharmaceuticals, Inc. has a twelve month low of $13.09 and a twelve month high of $35.66.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.05). The company had revenue of $24.27 million during the quarter, compared to analysts’ expectations of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. Equities analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.75 earnings per share for the current year.

Analysts Set New Price Targets

ETON has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. HC Wainwright boosted their target price on Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Tuesday, April 21st. Craig Hallum raised their price target on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Finally, Zacks Research downgraded Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, April 17th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $41.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ETON. Deutsche Bank AG grew its stake in shares of Eton Pharmaceuticals by 4.9% during the fourth quarter. Deutsche Bank AG now owns 18,249 shares of the company’s stock worth $309,000 after purchasing an additional 850 shares in the last quarter. Intech Investment Management LLC raised its position in shares of Eton Pharmaceuticals by 11.1% during the 4th quarter. Intech Investment Management LLC now owns 12,421 shares of the company’s stock worth $210,000 after acquiring an additional 1,244 shares in the last quarter. State of Wyoming lifted its stake in Eton Pharmaceuticals by 16.4% during the first quarter. State of Wyoming now owns 9,498 shares of the company’s stock worth $234,000 after purchasing an additional 1,337 shares during the last quarter. Man Group plc lifted its stake in Eton Pharmaceuticals by 6.0% during the second quarter. Man Group plc now owns 23,754 shares of the company’s stock worth $338,000 after purchasing an additional 1,350 shares during the last quarter. Finally, Quarry LP purchased a new stake in Eton Pharmaceuticals during the third quarter worth approximately $37,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.